Bai S, Tornello SL, Mogle JA, Feinberg ME. Daily implementation of health-protective behaviors and family life during the early months of the COVID-19 pandemic. Fam Process. 2024 Mar;63(1):428-42. doi: 10.1111/famp.12870.
Le Y, Mogle JA, Feinberg ME. Trajectories of parent and child well-being across the pandemic year: role of financial strain, social distancing, and COVID-19 prevalence. Fam Process. 2023 Sep;62(3):1134-46. doi: 10.1111/famp.12823
Feinberg ME, Gedaly L, Mogle J, Hostetler ML, Cifelli JA, Tornello SL, Lee JK, Jones DE. Building long-term family resilience through universal prevention: 10-year parent and child outcomes during the COVID-19 pandemic. Fam Process. 2022 Mar;61(1):76-90. doi: 10.1111/famp.12730
Jenkins AIC, Fredman SJ, Le Y, Mogle JA, McHale SM. Religious coping and gender moderate trajectories of marital love among black couples. Fam Process. 2022 Mar;61(1):312-25. doi: 10.1111/famp.12645
Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth. 2015 Jun;29(3):617-25. doi: 10.1053/j.jvca.2014.08.020
Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599
Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003 Oct 1;9(12):4396-403.
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.
Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res. 2003 Feb 1;9(2):762-6.